Gloria Biosciences’ Zimberelimab Receives NMPA’s Approval for Recurrent or Metastatic Cervical Cancer in China
Shots:
- The NMPA has approved Zimberelimab as monotx. for the treatment of patients with recurrent or metastatic cervical cancer with positive PD-L1 expression (CPS≥1) who progressed on or after Pt-based CT
- The approved was based on the P-II clinical trial results of zimberelimab (GLS-010) as monotx. As data cut off Apr 2022, the results showed ORR (27.8%) among 90 evaluable patients with tumor assessment, CR (5.6%), PR (22.2%), m-PFS was 3.7mos., m-OS (16.8mos.) & m-DoR had not been reached
- Zimberelimab, the first fully human anti-PD-1 mAb that has been developed by the transgenic rat platform, OmniRat was approved in China for r/r HL. The therapy also approved in China for cervical cancer
Ref: PR Newswire | Image: Gloria Biosciences
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
